证券代码：002219 证券简称：新里程 编号：2024-05 1 新里程健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------------|------------------------|-------|----------------------------------------------------------------| | | | | | | | □ 特定对象调研 | □ | 分析师会议 | | 投资者关系 | □ 媒体采访 | □ | 业绩说明会 | | 活动类别 | □ 新闻发布会 □ | | 路演活动 | | | □ 现场参观 | | | | | 其他：医保管理专题交流 | | | | | | | 东吴证券、兴业证券、海通证券、中信建投、天风证券、中信证券、 | | | | | 申万宏源、广发证券、国投证券、华安证券、首创证券、湘财证券、 | | | | | 中邮证券、平安证券、国泰君安、信达证券、光大证券、华泰证券、 | | | | | 民生证券、东北证券、国金证券、国联证券、国海证券、国盛证券、 | | | | ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-077 新里程健康科技集团股份有限公司 关于首次回购公司股份暨回购股份进展公告 1 新里程健康科技集团股份有限公司 公司于2024年9月18日通过回购专用证券账户以集中竞价交易方式回购股份 数量为5,607,000股，占公司目前总股本的0.1645%，最高成交价为1.80元/股，最 低成交价为1.76元/股，成交总金额10,017,709.00元（不含交易费用）。本次回购 符合相关法律法规、规范性文件及公司股份回购方案的规定。 二、其他说明 公司回购股份的时间、回购股份数量及集中竞价交易价格、集中竞价交易的 委托时段等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》 及公司回购股份方案的相关规定。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2024 年 8 月 1 日召开第六届董事会第二十四次会议、第六届监事会第十八次会 议，于 2024 年 8 月 19 日召开 2024 年第四次 ...

2024年9月4日，公司与招商银行股份有限公司郑州分行（以下简称"招商银 行郑州分行"）签署了《最高额不可撤销担保书》，公司为兰考第一医院有限公 司（以下简称"兰考一医院"）向招商银行郑州分行申请综合授信最高债权额人民 币3,000万元的流动资金贷款提供连带责任担保，最高额保证担保额度为人民币 3,000万元。 二、被担保人基本情况 新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-076 新里程健康科技集团股份有限公司 关于为下属医院提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2024 年 4 月 17 日召开第六届董事会第十八次会议，2024 年 5 月 10 日召开 2023 年 年度股东大会，审议通过了《关于为子公司提供担保额度预计的议案》，同意公 司为相关子公司未来 12 个月向相关合作银行等金融机构申请综合授信额度提供 连带责任担保，额度总计为人民币 194,900 万元（具体内容详见公司于 2024 ...

新里程健康科技集团股份有限公司 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号——回购股份》等相关规定，公司在回购股份期间，应于每个月的前3个交易 日内公告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至2024年8月31日，公司尚未实施股份回购。 1 新里程健康科技集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2024 年 8 月 1 日召开第六届董事会第二十四次会议、第六届监事会第十八次会 议，于 2024 年 8 月 19 日召开 2024 年第四次临时股东大会，审议通过了《关于 回购公司股份并减资注销方案的议案》。为维护公司价值及股东权益所必需，公 司拟使用自有或自筹资金以集中竞价交易方式回购公司部分股份，本次股份回购 后拟全部用于减少注册资本，具体内容详见公司 2024 年 8 月 2 日刊载于《证券 时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网（www.cninfo.com.cn） ...

新里程健康科技集团股份有限公司 投资者关系活动记录表 编号：2024-04 | --- | --- | --- | |------------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | 投资者关系 | □ 媒体采访 | 业绩说明会 | | 活动类别 | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | | | 兴业证券、海通证券、中信建投、东吴证券、天风证券、中信证券、 | | | | 中金公司、申万宏源、广发证券、西南证券、华安证券、首创证券、 | | | | 华鑫证券、湘财证券、中邮证券、华创证券、信达证券、招商证券、 | | | | 平安证券、光大证券、华泰证券、民生证券、东北证券、国联证券、 | | | | 国海证券、国盛 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a first-time coverage [2] Core Views - The company's hospital segment showed steady growth in H1 2024, with revenue increasing by 12.20% YoY to RMB 1.82 billion and net profit attributable to shareholders rising by 5.27% YoY to RMB 60 million [3] - The company's core hospitals demonstrated strong performance, with Wafangdian Third Hospital achieving an 8% YoY revenue growth to RMB 330 million and Lankao First Hospital growing 2.5% YoY to RMB 220 million [3] - The company's existing hospitals have high local market share and strong profitability, with a net profit margin of 9% in 2023 [4] - The company is expanding through new beds and asset injections, with plans to add 600 beds at Xuyi Hospital and 800 beds at Chongzhou Second Hospital [5] - The controlling shareholder plans to inject high-quality medical assets into the company within 5 years, potentially doubling the company's asset scale [6] Financial Performance - In H1 2024, the company's medical service revenue grew 2.98% YoY to RMB 1.45 billion, while pharmaceutical revenue surged 72.63% YoY to RMB 371 million [3] - The company's gross margin declined by 3.43 percentage points to 29.06% in H1 2024, mainly due to changes in business structure after acquiring Furen [3] - Operating cash flow increased by 15.5% YoY to RMB 145 million in H1 2024, while investment cash flow was -RMB 168 million and financing cash flow was -RMB 84 million [3] Expansion Plans - The company is actively expanding its hospital network, with new projects adding nearly 10,000 beds and existing bed utilization rate at around 90% [4] - Xuyi Hospital's new oncology building, adding 600 beds, started construction in October 2023, while Chongzhou Second Hospital's new 800-bed facility is expected to open in early 2025 [5] - Lankao First Hospital is preparing to establish a tumor center, and Siyang Hospital has obtained a license for a geriatric hospital and is applying for a tumor hospital license [6] Financial Projections - The company's revenue is expected to grow from RMB 4.105 billion in 2024 to RMB 5.838 billion in 2026, with net profit attributable to shareholders projected to increase from RMB 114.79 million to RMB 352.11 million [7][9] - EPS is forecasted to rise from RMB 0.03 in 2024 to RMB 0.10 in 2026, with P/E ratios decreasing from 51.67x to 16.84x over the same period [7][9] - The company's gross margin is expected to remain stable at around 29.5%-29.9% from 2024 to 2026, with net profit margin increasing from 2.8% to 6.0% [11]

Investment Rating - The report assigns a "Hold" rating for the company [6] Core Insights - The company achieved a revenue growth of 12.20% year-on-year in H1 2024, with a net profit growth of 5.27% [2] - The company is expected to inject high-quality external hospital assets in the future, which could enhance its operational capacity and market position [6] Financial Performance - In H1 2024, the company reported revenue of 1.82 billion yuan, a 12.20% increase year-on-year, and a net profit of 60 million yuan, up 5.27% [2] - The second quarter of 2024 saw revenue of 957 million yuan, reflecting a 14.41% year-on-year growth, while net profit was 36 million yuan, a 1.02% increase [2] - The company's gross margin for H1 2024 was 29.06%, down 3.71 percentage points from the previous year, and the net margin was 3.42%, down 0.34 percentage points [3] Cost Management - The company's management expense ratio decreased significantly to 14.46%, down 2.94 percentage points year-on-year, attributed mainly to reduced equity incentive costs [3] - The financial expense ratio increased to 3.41%, up 0.18 percentage points year-on-year [3] Healthcare Services - The healthcare services segment generated revenue of 1.45 billion yuan in H1 2024, a 2.98% increase year-on-year [4] - The company plans to expand its bed capacity, with several new hospital projects underway, including a new oncology specialty building and a new hospital district [4] Pharmaceutical Business - The pharmaceutical and medical products segment achieved revenue of 371 million yuan in H1 2024, a remarkable 72.63% increase year-on-year [5] - The company is leveraging its well-known "Duyiwei" brand to develop a line of oral care products, entering the fast-moving consumer goods market [5] Future Projections - Revenue projections for 2024-2026 are estimated at 3.993 billion yuan, 4.400 billion yuan, and 4.835 billion yuan, respectively, with net profits expected to be 128.2 million yuan, 184.1 million yuan, and 237.7 million yuan [6][7]

Investment Rating - The investment rating for the company is "Buy - A" with a target price of 2.04 CNY for the next six months [5]. Core Views - The company reported stable main business performance, with a focus on the progress of private placements [8]. - The company maintains a dual-driven business model of "medical + pharmaceutical," with the medical services segment showing steady growth and the pharmaceutical segment actively expanding [2][8]. - The overall gross margin has faced temporary pressure, but the operating net profit attributable to the parent company exceeded 100 million CNY [3]. Financial Performance - In the first half of 2024, the company achieved operating revenue of 1.82 billion CNY, a year-on-year increase of 12.20%, and a net profit attributable to the parent company of 60 million CNY, up 5.27% year-on-year [1]. - The medical services segment generated revenue of 1.45 billion CNY, a 2.98% increase year-on-year, while the pharmaceutical segment saw revenue of 371 million CNY, a significant increase of 72.63% [2]. - The overall gross margin for the first half of 2024 was 29.06%, down 3.70 percentage points year-on-year, with the medical services gross margin at 24.76% and the pharmaceutical gross margin at 45.86% [3]. Strategic Initiatives - The company emphasizes discipline construction and improving medical quality, having added six provincial and municipal key specialties in the first half of 2024 [4]. - The company is actively expanding its existing hospital construction, with new projects underway to increase bed capacity significantly [8]. - The company is focusing on both internal growth and external acquisitions, with plans to inject profitable medical assets into the listed company [8]. Future Projections - Revenue projections for 2024 to 2026 are 4.01 billion CNY, 4.40 billion CNY, and 4.83 billion CNY, respectively, with net profits expected to be 122 million CNY, 224 million CNY, and 300 million CNY [9].

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-073 新里程健康科技集团股份有限公司 第六届监事会第十九次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届监事会第十九次会议通知于2024年8月12日以书面、电子邮件、电话送达等方 式发出，会议于2024年8月22日以现场表决结合通讯方式表决在公司会议室召开。 会议由公司监事会主席李海涛先生召集并主持，公司现任监事3名，实际表决监 事3名，符合《公司法》和《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 经与会监事审议，会议审议通过了以下议案并做出如下决议： （一）审议通过《关于公司<2024 年半年度报告>及<2024 年半年度报告摘 要>的议案》 经审核，监事会认为董事会编制和审核的新里程健康科技集团股份有限公司 《2024年半年度报告》及《2024年半年度报告摘要》的程序符合法律、行政法规 和中国证监会的规定，报告内容真实、准确、完整地 ...

新里程健康科技集团股份有限公司 一、董事会会议召开情况 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）第六 届董事会第二十五次会议于 2024 年 8 月 12 日以书面、电话、电子邮件等形式发 出，会议于 2024 年 8 月 22 日在公司会议室以现场表决结合通讯表决的方式召开， 本次会议由公司董事长林杨林先生主持，公司现任董事 11 名，实际表决董事 11 名，公司监事及高级管理人员列席本次会议，会议的召开与表决程序符合《公司 法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，审议通过了以下议案并形成决议。 （一）审议通过《关于公司<2024 年半年度报告>及<2024 年半年度报告摘 要>的议案》 经审议，公司《2024年半年度报告》及《2024年半年度报告摘要》内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏，同意《关于公司<2024年半年度报告>及<2024年半年度报告摘要>的议 案》。 证券简称：新里程 证券代码：002219 公告编号：2024-072 新里程健康科技集团股份有限公司 第六届董 ...